NCT00559273 · OUTCOME

Percentage of Participants Who Had at Least 1 Hemoglobin Value Exceeding 12.0 g/dL

A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis · Source last updated 2016-11-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: Not reported
Time frame: Baseline to Week 8

What was measured

Percentage of participants having at least one Hb value greater than (\>) 12 g/dL during the first 8 weeks of the study was reported.

Analysis population: ITT population. Here, N=number of participants evaluable for this measure.

Groups in this outcome

Mircera

Participants received Mircera (Methoxy polyethylene glycol-epoetin beta), administered SC at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.

Darbepoetin Alfa

Participants received darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Mircera	151
Darbepoetin Alfa	151

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Mircera	25.8	Not reported	Not reported	Not reported	Not reported
Darbepoetin Alfa	47.7	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
25.8
group Id
OG001
value
47.7

denoms

counts
group Id
OG000
value
151
group Id
OG001
value
151
units
Participants

description

Percentage of participants having at least one Hb value greater than (\>) 12 g/dL during the first 8 weeks of the study was reported.

groups

description
Participants received Mircera (Methoxy polyethylene glycol-epoetin beta), administered SC at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
id
OG000
title
Mircera
description
Participants received darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.
id
OG001
title
Darbepoetin Alfa

param Type

NUMBER

population Description

ITT population. Here, N=number of participants evaluable for this measure.

reporting Status

POSTED

time Frame

Baseline to Week 8

title

Percentage of Participants Who Had at Least 1 Hemoglobin Value Exceeding 12.0 g/dL

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice